Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA Holdings Inc. (NYSE:IQV) announced the appointment of Costa Panagos as president of its Research & Development Solutions unit, succeeding Richard Staub III, who is retiring after over three decades. Panagos, with 25 years of industry experience, was previously the president of R&D Operations and CEO of Q2 Solutions. His effective date is April 1, 2022. Richard Staub will remain with the company as a senior advisor, aiding in business development and client management. This transition is expected to be quick and seamless, as per CEO Ari Bousbib.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will speak at the Barclays Global Healthcare Conference in Miami, FL on March 16, 2022, at 1:35 p.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics and clinical research services for the life sciences sector, operating in over 100 countries with approximately 79,000 employees and focusing on improving healthcare outcomes through innovative solutions.
IQVIA has entered into a multi-year collaboration with argenx SE to develop new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved treatment for generalized myasthenia gravis. The undisclosed terms of the agreement will enhance clinical development, regulatory, and commercial strategies. IQVIA aims to support argenx in accelerating this process, leveraging its expertise in analytics and technology. With approximately 79,000 employees operating in over 100 countries, IQVIA continues to emphasize its role in improving healthcare outcomes.
IQVIA Holdings reported a strong fourth quarter with revenue of $3,636 million, up 10.2% year-over-year. GAAP net income surged by 167.2% to $318 million, translating to earnings per share of $1.63. Adjusted EBITDA reached $828 million, representing a 12.7% increase. For 2022, IQVIA reaffirmed its revenue guidance of $14.7 billion to $15 billion and raised expectations for Adjusted EBITDA and Earnings per Share. The contracted backlog in R&D Solutions grew to $24.8 billion, indicating strong future revenue potential.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 11:00 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is a global leader in analytics and clinical research services for life sciences, operating in over 100 countries with approximately 79,000 employees, focusing on improving healthcare outcomes through insights and technology.
IQVIA Holdings Inc. (NYSE: IQV) will release its fourth-quarter and full-year 2021 financial results on February 15, 2022, before the market opens. The management team will present a conference call at 9:00 a.m. Eastern Time on the same day. Interested participants can register in advance via the Investor Relations website. A replay of the event will be available two hours post conclusion. IQVIA is a leader in analytics and clinical research, supporting healthcare improvements across its operations in over 100 countries.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
